US20220023202A1 - Medicated Hard Candy Product For Treating Esophageal Inflammation And A Method Using The Same - Google Patents
Medicated Hard Candy Product For Treating Esophageal Inflammation And A Method Using The Same Download PDFInfo
- Publication number
- US20220023202A1 US20220023202A1 US17/493,698 US202117493698A US2022023202A1 US 20220023202 A1 US20220023202 A1 US 20220023202A1 US 202117493698 A US202117493698 A US 202117493698A US 2022023202 A1 US2022023202 A1 US 2022023202A1
- Authority
- US
- United States
- Prior art keywords
- hard candy
- medicated
- candy product
- corticosteroid
- lollipop
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 48
- 206010061218 Inflammation Diseases 0.000 title claims abstract description 24
- 230000004054 inflammatory process Effects 0.000 title claims abstract description 24
- 235000009508 confectionery Nutrition 0.000 claims abstract description 120
- 235000011475 lollipops Nutrition 0.000 claims abstract description 118
- 239000003246 corticosteroid Substances 0.000 claims abstract description 49
- 239000000463 material Substances 0.000 claims abstract description 43
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 claims abstract description 40
- 201000000708 eosinophilic esophagitis Diseases 0.000 claims abstract description 40
- 239000007937 lozenge Substances 0.000 claims abstract description 34
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims abstract description 23
- 229960004436 budesonide Drugs 0.000 claims abstract description 23
- 208000024891 symptom Diseases 0.000 claims abstract description 10
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims abstract description 6
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 claims abstract description 6
- 229950000210 beclometasone dipropionate Drugs 0.000 claims abstract description 6
- 229960003728 ciclesonide Drugs 0.000 claims abstract description 6
- 229960002714 fluticasone Drugs 0.000 claims abstract description 6
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims abstract description 6
- 229960002744 mometasone furoate Drugs 0.000 claims abstract description 6
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 239000000843 powder Substances 0.000 claims description 5
- 210000003238 esophagus Anatomy 0.000 description 25
- 239000004615 ingredient Substances 0.000 description 16
- 229940079593 drug Drugs 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 230000002093 peripheral effect Effects 0.000 description 10
- 230000000843 anti-fungal effect Effects 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 210000003979 eosinophil Anatomy 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 235000013305 food Nutrition 0.000 description 6
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 6
- 238000001574 biopsy Methods 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 244000246386 Mentha pulegium Species 0.000 description 4
- 235000016257 Mentha pulegium Nutrition 0.000 description 4
- 235000004357 Mentha x piperita Nutrition 0.000 description 4
- 238000004040 coloring Methods 0.000 description 4
- 235000020882 elemental diet Nutrition 0.000 description 4
- 210000000416 exudates and transudate Anatomy 0.000 description 4
- 239000011888 foil Substances 0.000 description 4
- 235000014105 formulated food Nutrition 0.000 description 4
- 239000008369 fruit flavor Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 235000001050 hortel pimenta Nutrition 0.000 description 4
- 229960000988 nystatin Drugs 0.000 description 4
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 3
- 206010050346 Oropharyngeal candidiasis Diseases 0.000 description 3
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 3
- 239000000828 canola oil Substances 0.000 description 3
- 235000019519 canola oil Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 238000001839 endoscopy Methods 0.000 description 3
- VHVPQPYKVGDNFY-ZPGVKDDISA-N itraconazole Chemical compound O=C1N(C(C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-ZPGVKDDISA-N 0.000 description 3
- 150000005846 sugar alcohols Chemical class 0.000 description 3
- 244000089742 Citrus aurantifolia Species 0.000 description 2
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 2
- 206010030154 Oesophageal candidiasis Diseases 0.000 description 2
- 208000007027 Oral Candidiasis Diseases 0.000 description 2
- 229960003942 amphotericin b Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000007958 cherry flavor Substances 0.000 description 2
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 208000002925 dental caries Diseases 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 201000005655 esophageal candidiasis Diseases 0.000 description 2
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 2
- 229960002509 miconazole Drugs 0.000 description 2
- 239000007967 peppermint flavor Substances 0.000 description 2
- RAGOYPUPXAKGKH-XAKZXMRKSA-N posaconazole Chemical compound O=C1N([C@H]([C@H](C)O)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3C[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 RAGOYPUPXAKGKH-XAKZXMRKSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229940063138 sporanox Drugs 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- 241000208140 Acer Species 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- -1 Bio-Statin Chemical compound 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 241000675108 Citrus tangerina Species 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 240000001238 Gaultheria procumbens Species 0.000 description 1
- 235000007297 Gaultheria procumbens Nutrition 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 235000019596 Masking bitterness Nutrition 0.000 description 1
- 235000014749 Mentha crispa Nutrition 0.000 description 1
- 244000024873 Mentha crispa Species 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- 244000294611 Punica granatum Species 0.000 description 1
- 235000014360 Punica granatum Nutrition 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 240000001987 Pyrus communis Species 0.000 description 1
- 240000007651 Rubus glaucus Species 0.000 description 1
- 235000011034 Rubus glaucus Nutrition 0.000 description 1
- 235000009122 Rubus idaeus Nutrition 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 240000000851 Vaccinium corymbosum Species 0.000 description 1
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 1
- 240000001717 Vaccinium macrocarpon Species 0.000 description 1
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 229940056854 bio-statin Drugs 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 235000021014 blueberries Nutrition 0.000 description 1
- 210000005178 buccal mucosa Anatomy 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 230000001013 cariogenic effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000004634 cranberry Nutrition 0.000 description 1
- ZXJXZNDDNMQXFV-UHFFFAOYSA-M crystal violet Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1[C+](C=1C=CC(=CC=1)N(C)C)C1=CC=C(N(C)C)C=C1 ZXJXZNDDNMQXFV-UHFFFAOYSA-M 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 229940063123 diflucan Drugs 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229960001235 gentian violet Drugs 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940049018 mycostatin Drugs 0.000 description 1
- 229940099075 noxafil Drugs 0.000 description 1
- 229940048490 onmel Drugs 0.000 description 1
- 229940100692 oral suspension Drugs 0.000 description 1
- 229940112153 oravig Drugs 0.000 description 1
- 229960001589 posaconazole Drugs 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 235000021092 sugar substitutes Nutrition 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000015149 toffees Nutrition 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Definitions
- the invention generally relates to a medicated hard candy product. More particularly, the invention relates to a medicated hard candy product for treating esophageal inflammation and a method using the same.
- Eosinophilic esophagitis is an allergic inflammatory condition of the esophagus that involves eosinophiles, a type of white blood cell.
- the typical symptoms of eosinophilic esophagitis (EoE) are difficulty swallowing, food impaction, and heartburn.
- EoE eosinophilic esophagitis
- One of the limited ways of treating eosinophilic esophagitis is with an elemental diet, or by removing allergenic foods. The dietary management approach is very challenging for the patient, and is often met with great resistance in adults and children alike.
- the overall treatment goal for eosinophilic esophagitis is to prevent the damaging inflammation that occurs due to migration of eosinophiles into the esophagus. If eosinophilic esophagitis is left untreated, the patient will gradually lose the ability to swallow, and eventually will be forced onto a feeding tube in order to survive.
- a medicated hard candy product for treating esophageal inflammation that effectively treats eosinophilic esophagitis without subjecting the patient to the unpleasant limitations of an elemental diet.
- a medicated hard candy product is needed that sufficiently coats substantially the full length of the peripheral wall of the esophagus so as to effectively treat eosinophilic esophagitis throughout the entire esophagus.
- a medicated hard candy product that effectively treats eosinophilic esophagitis without a significant portion of the swallowed medicated product being wasted by failing to contact the esophagus wall.
- a treatment method using a medicated hard candy product that has the abovementioned attributes.
- the present invention is directed to a medicated hard candy product for treating esophageal inflammation and a method using the same that substantially obviates one or more problems resulting from the limitations and deficiencies of the related art.
- a medicated hard candy product that includes a hard candy base material, the hard candy base material forming a substantially rigid candy product after being heated and permitted to cool for a predetermined time period; and a corticosteroid, the corticosteroid being intermixed with the hard candy base material.
- the medicated hard candy product is configured to reduce or alleviate esophageal inflammation or symptoms associated therewith in an individual when orally administered thereto.
- the hard candy base material comprises a sugar-free dry powder base prior to being heated.
- the corticosteroid comprises one of: (i) budesonide, (ii) fluticasone, (iii) ciclesonide, (iv) beclomethasone dipropionate, and (v) mometasone furoate.
- the medicated hard candy product comprises between approximately 0.25 milligrams and approximately 1.0 milligrams of the corticosteroid.
- the medicated hard candy product contains no water after being heated and permitted to cool for the predetermined time period.
- no water is used in the process of making the medicated hard candy product.
- the medicated hard candy product is in the form of a lollipop or sucker.
- the medicated hard candy product is in the form of a lozenge.
- a medicated hard candy product that includes a hard candy base material, the hard candy base material forming a substantially rigid candy product after being heated and permitted to cool for a predetermined time period; and a corticosteroid, the corticosteroid being intermixed with the hard candy base material, the corticosteroid comprising one of: (i) budesonide, (ii) fluticasone, (iii) ciclesonide, (iv) beclomethasone dipropionate, and (v) mometasone furoate.
- the medicated hard candy product is configured to reduce or alleviate esophageal inflammation or symptoms associated therewith in an individual when orally administered thereto; and the medicated hard candy product is in the form of a lollipop or a lozenge.
- the hard candy base material comprises a sugar-free dry powder base prior to being heated.
- the medicated hard candy product contains no water after being heated and permitted to cool for the predetermined time period.
- no water is used in the process of making the medicated hard candy product.
- the medicated hard candy product is in the form of a lollipop.
- the medicated hard candy product is in the form of a lozenge.
- a method of treating, reducing, or alleviating esophageal inflammation in an individual comprising orally administering to the individual a medicated hard candy product, the medicated hard candy product comprising a hard candy base material, the hard candy base material forming a substantially rigid candy product after being heated and permitted to cool for a predetermined time period; and a corticosteroid, the corticosteroid being intermixed with the hard candy base material, the corticosteroid comprising one of: (i) budesonide, (ii) fluticasone, (iii) ciclesonide, (iv) beclomethasone dipropionate, and (v) mometasone furoate.
- the hard candy base material comprises a sugar-free dry powder base prior to being heated.
- the medicated hard candy product contains no water after being heated and permitted to cool for the predetermined time period.
- no water is used in the process of making the medicated hard candy product.
- the medicated hard candy product is in the form of a lollipop or sucker.
- the medicated hard candy product is in the form of a lozenge.
- FIG. 1 is a perspective view of a medicated lollipop for treating esophageal inflammation, according to an embodiment of the invention, wherein the lollipop is illustrated with the wrapper thereon;
- FIG. 2 is another perspective view of the medicated lollipop of FIG. 1 , wherein the lollipop is illustrated with the wrapper removed therefrom;
- FIG. 3 is a top view of the medicated lollipop of FIG. 2 ;
- FIG. 4 is a front view of the medicated lollipop of FIG. 2 ;
- FIG. 5 is a side view of the medicated lollipop of FIG. 2 ;
- FIG. 6 is a transverse sectional view of the medicated lollipop of FIG. 2 , wherein the section is cut along the cutting plane line A-A in FIG. 7 ;
- FIG. 7 is another front view of the medicated lollipop of FIG. 2 , wherein the section cut lines are illustrated thereon;
- FIG. 8 is a longitudinal sectional view of the medicated lollipop of FIG. 2 , wherein the section is cut along the cutting plane line B-B in FIG. 7 ;
- FIG. 9 is a perspective view of a medicated lozenge for treating esophageal inflammation, according to an embodiment of the invention, wherein the lozenge is illustrated with the wrapper thereon;
- FIG. 10 is another perspective view of the medicated lozenge of FIG. 9 , wherein the lozenge is illustrated with the wrapper removed therefrom;
- FIG. 11 is a side view of the medicated lozenge of FIG. 10 ;
- FIG. 12 is a top view of the medicated lozenge of FIG. 10 , wherein the section cut lines are illustrated thereon;
- FIG. 13 is an end view of the medicated lozenge of FIG. 10 ;
- FIG. 14 is a transverse sectional view of the medicated lozenge of FIG. 10 , wherein the section is cut along the cutting plane line C-C in FIG. 12 ;
- FIG. 15 is a longitudinal sectional view of the medicated lozenge of FIG. 10 , wherein the section is cut along the cutting plane line D-D in FIG. 12 ;
- FIG. 16 illustrates a post-treatment biopsy slide for a patient that was treated using the medicated hard candy product of the present invention.
- an orally-administered medicated hard candy product that reduces or alleviates esophageal inflammation and/or symptoms associated therewith in an individual when orally administered thereto.
- the medicated hard candy reduces or alleviates esophageal inflammation that is caused by eosinophilic esophagitis (EoE).
- the medicated hard candy product generally comprises a hard candy base material, the hard candy base material forming a rigid or substantially rigid candy product after being heated and permitted to cool for a predetermined time period; and a corticosteroid, the corticosteroid being intermixed with the hard candy base material.
- the corticosteroid may comprise budesonide, fluticasone, ciclesonide, beclomethasone dipropionate, mometasone furoate, or another type of corticosteroid suitable for reducing or alleviating esophageal inflammation.
- the hard candy base material of the medicated hard candy product may comprise a sugar-free dry powder base that is suitable for preparing hand candy that can be orally administered and absorbed across the sublingual or buccal mucosa.
- the hard candy base material may have a very low hygroscopicity, bitterness masking, and a low caloric value.
- the hard candy base material may also be non-cariogenic such that it does not promote tooth decay of the patient.
- the hard candy base material may comprise Lollibase® as manufactured by Fagron Group BV.
- the medicated hard candy product may also include flavoring and sweeteners (e.g., sugar or a sugar substitute).
- the hard candy product may have a peppermint flavor or a fruit flavor (e.g., cherry flavor).
- colors may be added to the hard candy mixture (e.g., the hard candy could be red, green, blue, or any other color that is desired).
- the medicated hard candy product is in the form of a medicated lollipop or sucker 10 .
- the medicated lollipop 10 generally comprises lollipop body portion 12 disposed on a stick member 14 .
- the stick member 14 is embedded into the lollipop body portion 12 and serves as a handle for the user of the medicated lollipop 10 (see FIG. 8 ).
- the lollipop body portion 12 may comprise a foil wrapper 16 disposed therearound for hygienic purposes. When the user or patient is ready to consume the medicated lollipop 10 , he or she simply removes the foil wrapper 16 from the lollipop body portion 12 .
- the lollipop body portion 12 comprises a generally planar front surface 12 a, a tapered circular side surface 12 b, and a generally planar rear surface 12 c. As best shown in FIGS. 3 and 6 , the front surface 12 a is disposed generally parallel to the rear surface 12 c. Also, with reference to FIGS. 3 and 5 , it can be seen that the lollipop body portion 12 is provided with a rounded front peripheral edge 18 . In FIG.
- the rounded front peripheral edge 18 is provided at the location where the front surface 12 a adjoins the tapered circular side surface 12 b.
- the rounded front peripheral edge 18 of the lollipop body portion 12 substantially minimizes the risk that a user of the medicated lollipop 10 will inadvertently cut his or her tongue on a sharp edge of the lollipop body portion 12 .
- the medicated hard candy product is in the form of a medicated lozenge 20 .
- the medicated lozenge 20 generally comprises an ellipsoidal body portion 22 with flattened top and bottom surfaces.
- the lozenge body portion 22 may comprise a foil wrapper 24 disposed therearound for hygienic purposes. When the user or patient is ready to consume the medicated lozenge 20 , he or she simply removes the foil wrapper 24 from the lozenge body portion 22 .
- the lozenge body portion 22 comprises a generally planar front surface 22 a, a curved side surface 22 b, and a generally planar rear surface 22 c. As best shown in FIGS. 11 and 13-15 , the front surface 22 a is disposed generally parallel to the rear surface 22 c. Also, with reference again to FIGS. 11 and 13-15 , it can be seen that the lozenge body portion 22 is provided with a rounded peripheral edges 26 circumscribing the front and rear edges thereof.
- the rounded peripheral edges 26 are provided at the location where the front surface 22 a adjoins the curved side surface 22 b and at the location where the rear surface 22 c adjoins the curved side surface 22 b.
- the rounded peripheral edges 26 of the lozenge body portion 22 substantially minimize the risk that a user of the medicated lozenge 20 will inadvertently cut his or her tongue on a sharp edge of the lozenge body portion 22 .
- the medicated hard candy product (e.g., the lollipop 10 or the lozenge 20 ) may comprise between approximately 0.1 milligrams and approximately 2.0 milligrams of the corticosteroid (e.g., budesonide), or between 0.1 milligrams and 2.0 milligrams of the corticosteroid (e.g., budesonide).
- the medicated hard candy product (e.g., the lollipop 10 or the lozenge 20 ) may comprise between approximately 0.25 milligrams and approximately 1.0 milligrams of the corticosteroid (e.g., budesonide), or between 0.25 milligrams and 1.0 milligrams of the corticosteroid (e.g., budesonide).
- the corticosteroid e.g., budesonide
- the corticosteroid e.g., budesonide
- the medicated hard candy product may comprise approximately 0.5 milligrams of the corticosteroid (e.g., budesonide), or 0.5 milligrams of the corticosteroid (e.g., budesonide).
- the amounts (in units of mass) of the corticosteroid in these embodiments have been determined such that the amount of the corticosteroid is sufficient to effectively reduce or alleviate esophageal inflammation and/or the symptoms associated therewith in an individual caused by eosinophilic esophagitis (EoE), yet not result in an excessive amount of the corticosteroid being delivered to the individual, which may produce negative side effects therefrom.
- EoE eosinophilic esophagitis
- ranges of a particular substance e.g., a corticosteroid
- the ranges are inclusive of the values encompassed within the specified range and the upper and lower limit boundaries themselves (e.g., between 0.1 and 2.0 milligrams includes the milligram values between the lower limit of 0.1 milligrams and the upper limit of 2.0 milligrams, as well as the lower and upper limit values of 0.1 and 2.0 milligrams).
- the overall mass of the lollipop 10 may be between approximately 4.0 grams and approximately 17.0 grams (or between 4.0 grams and 17.0 grams). More preferably, in one or more embodiments, when the medicated hard candy product is provided in the form of the medicated lollipop 10 , the overall mass of the lollipop 10 may be between approximately 6.5 grams and approximately 12.0 grams (or between 6.5 grams and 12.0 grams). Still even more preferably, in one or more embodiments, the overall mass of the lollipop 10 may be approximately 8.5 grams (or 8.5 grams). The overall masses of the lollipop 10 in these embodiments have been determined such that the lollipop 10 is capable of delivering a requisite amount of the corticosteroid, yet not be excessively large and difficult to consume.
- the medicated lollipop 10 when the medicated hard candy product is provided in the form of the medicated lollipop 10 , the medicated lollipop 10 has an overall mass with the stick member 14 of approximately 9.141 grams, and has an overall mass without the stick member 14 of approximately 8.437 grams. In this exemplary embodiment, the medicated lollipop 10 is provided with 1.0 milligram or 0.001 grams of budesonide, so that the medicated lollipop 10 contains approximately 0.0119 percent budesonide by weight (i.e., without considering the weight of the stick member 14 ).
- the medicated lollipop 10 may contain at least 0.003 percent of the corticosteroid (e.g., budesonide) by weight (i.e., 0.25 milligrams of the corticosteroid in a medicated lollipop 10 weighing 8.5 grams without the stick member 14 ) so that the amount of the corticosteroid is sufficient to effectively reduce or alleviate esophageal inflammation and/or the symptoms associated esophageal inflammation in an individual caused by eosinophilic esophagitis (EoE).
- the corticosteroid e.g., budesonide
- the top end of the lollipop stick member 14 is coated with an anti-fungal medication.
- the anti-fungal medication on the top end of the lollipop stick member 14 treats oropharyngeal candidiasis (i.e., oral and esophageal thrush), which may be caused by the corticosteroid delivered by the medicated lollipop 10 .
- the patient initially consumes the lollipop body portion 12 that delivers the corticosteroid for treating eosinophilic esophagitis (EoE), and then the patient subsequently receives a predetermined dosage of the anti-fungal medication on the top end of the lollipop stick member 14 , which has been exposed after the lollipop body portion 12 has been consumed, for treating the oropharyngeal candidiasis.
- This inventive two-step treatment method not only effectively treats eosinophilic esophagitis (EoE), but also effectively treats any oropharyngeal candidiasis resulting from the consumption of the corticosteroid in the lollipop 10 .
- the anti-fungal medication applied to the top end of the lollipop stick member 14 may comprise nystatin, Diflucan, fluconazole, Mycelex Troche, clotrimazole, Mycostatin, Nilstat, Bio-Statin, miconazole, ketoconazole, Amphocin, Sporanox PulsePak, Fungizone, gentian violet, itraconazole, amphotericin b, miconazole, Oravig, Sporanox, Noxafil, Onmel, and posaconazole, or another type of anti-fungal medication suitable for reducing or alleviating oral and/or esophageal thrush.
- the top end of the lollipop stick member 14 may have a peppermint flavor or a fruit flavor (e.g., a cherry flavor) to make the unpleasant flavor (e.g., bitter flavor) of the anti-fungal medication more tolerable for the patient.
- a peppermint flavor or a fruit flavor e.g., a cherry flavor
- the anti-fungal medication applied to the top end of the lollipop stick member 14 is nystatin. Nystatin is not absorbed into the bloodstream of the patient.
- the dosage of nystatin provided on the lollipop stick member 14 is functionally equivalent to 400,000 to 600,000 international units (IU) in an oral suspension form. In this exemplary embodiment, this dosage is administered to the patient four times per day.
- the necessary quantities (e.g., percentage amounts) of each of the requisite ingredients for the medicated lollipop 10 are determined (i.e., calculated) and procured.
- these prescribed quantities of ingredients are dependent upon the lollipop batch size that is to be made.
- a predetermined quantity of the following ingredients will be prepared for the batch of medicated lollipops 10 : (i) a predetermined quantity of a corticosteroid (e.g., budesonide), (ii) a predetermined quantity of water, and (iii) a predetermined quantity of the hard candy base material (e.g., Lollibase®).
- a flavoring substance e.g., peppermint or a fruit flavor
- a coloring substance may also be added as another optional ingredient in the mixture.
- the next step in the exemplary procedure is to add the hard candy base material and the water into a suitable beaker. Then, the solution of the hard candy base material and the water are heated or “cooked” using a suitable heating device (e.g., a hotplate). Next, when the solution reaches a temperature of approximately 148 degrees Celsius (298.4 degrees Fahrenheit), the beaker with the solution of the hard candy base material and water are removed from the heating device (e.g., a hotplate). Then, the corticosteroid (e.g., budesonide) and the optional flavoring are quickly added to the solution, and the solution is stirred so as to adequately mix the constituent ingredients.
- a suitable heating device e.g., a hotplate
- the solution is poured into lollipop or sucker molds that form the shape of the medicated lollipops 10 .
- the lollipop molds Prior to pouring the solution into the molds, the lollipop molds are basted with a non-sticking substance (e.g., canola oil) and the lollipop sticks 14 are properly positioned in the molds. If the solution begins to solidify or harden before it is completely poured into all of the lollipop molds, it may be necessary to reheat the solution, and then finish the pouring thereof into the molds.
- a non-sticking substance e.g., canola oil
- the lollipops are allowed to cool and solidify for a predetermined time period (e.g., for a duration of at least two (2) hours) before they are wrapped with the wrappers 16 .
- a predetermined time period e.g., for a duration of at least two (2) hours
- the final medicated hard candy product (e.g., the medicated lollipop 10 ) contains no residual water therein because all of the water is boiled off when the solution is heated to a temperature of approximately 148 degrees Celsius (298.4 degrees Fahrenheit).
- the second exemplary procedure for making the medicated lollipop 10 is similar in most respects to the first exemplary procedure described above, except that no water is used in the process of making the medicated lollipop 10 .
- the necessary quantities e.g., percentage amounts
- these prescribed quantities of ingredients are dependent upon the lollipop batch size that is to be made.
- a predetermined quantity of the following ingredients will be prepared for the batch of medicated lollipops 10 : (i) a predetermined quantity of a corticosteroid (e.g., budesonide) and (ii) a predetermined quantity of the hard candy base material (e.g., Lollibase®).
- a flavoring substance e.g., peppermint or a fruit flavor
- a coloring substance may also be added as another optional ingredient in the mixture.
- the next step in the second exemplary procedure is to fill a suitable beaker with the hard candy base material.
- the hard candy base material in the beaker is heated or “cooked” using a suitable heating device (e.g., a hotplate).
- a suitable heating device e.g., a hotplate
- the beaker with the liquefied hard candy base material is removed from the heating device (e.g., a hotplate).
- the corticosteroid (e.g., budesonide) and the optional flavoring are quickly added to the liquefied hard candy base material, and the solution is stirred so as to adequately mix the constituent ingredients.
- the solution is poured into lollipop or sucker molds that form the shape of the medicated lollipops 10 .
- the lollipop molds Prior to pouring the solution into the molds, the lollipop molds are basted with a non-sticking substance (e.g., canola oil) and the lollipop sticks 14 are properly positioned in the molds. If the solution begins to solidify or harden before it is completely poured into all of the lollipop molds, it may be necessary to reheat the solution, and then finish the pouring thereof into the molds.
- a non-sticking substance e.g., canola oil
- the lollipops are allowed to cool and solidify for a predetermined time period (e.g., for a duration of at least two (2) hours) before they are wrapped with the wrappers 16 .
- a predetermined time period e.g., for a duration of at least two (2) hours
- the top ends of the lollipop sticks 14 are initially coated with the anti-fungal medication (i.e., in stage one), and then the lollipop sticks 14 are subsequently positioned in the molds so that the solution containing the corticosteroid and the hard candy base material is able to solidify on the lollipop sticks 14 (i.e., in stage two).
- the shelf life of the medicated lollipop 10 is increased from 30 days (i.e., when water is used in the process) to a shelf life of 6 months (i.e., when no water is used in the process).
- the hard candy base material i.e., lollipop base material used in the abovedescribed procedure is gluten-free, citric acid free, and sugar free.
- the hard candy base material generally comprises a blend or mixture of sugar alcohols (i.e., polyalcohols) from natural sources. Because the hard candy base material is a polyalcohol, it turns into a liquid when boiled. Also, in these one or more embodiments, the hard candy base material does not promote tooth decay.
- the other main ingredients utilized in the process of making the lollipops, other than water are a corticosteroid in the form of budesonide, pure canola oil to prevent the lollipops from sticking to the mold(s), and the optional natural flavor or flavors (e.g., peppermint).
- the following other natural flavors may be utilized in the solution used for making the medicated lollipops 10 : almond, banana, blueberry, cherry, chocolate, cranberry, cinnamon, caramel, maple, pomegranate, raspberry, strawberry, toffee, licorice, lemon, orange, grapefruit, key lime, lime, pear, spearmint, tangerine, and wintergreen.
- EoE Eosinophilic Esophagitis
- the treatment procedure was performed on the EoE patient for a time duration of approximately six (6) weeks.
- the patient orally ingested two (2) medicated lollipops 10 Each of the medicated lollipops 10 contained approximately 0.5 milligrams (MG) of budesonide.
- MG milligrams
- the dosage of medication (budesonide) that the patient received during the treatment procedure was generally 0.5 MG BID (i.e., twice per day).
- the shelf life of the medicated lollipops 10 that were used during the treatment was approximately six (6) months.
- the medicated lollipops 10 that were used during the treatment were peppermint-flavored, but because the flavoring is in no way connected to the medication itself, it is readily apparent that other flavors, or medicated lollipops 10 with no flavoring would have the same result as the lollipops 10 used in this treatment procedure.
- the medicated lollipops 10 that were used during the treatment were clear (i.e., they had no coloring added thereto), but because the coloring, like the flavoring, is in no way connected to the medication itself, it is readily apparent that medicated lollipops 10 having a particular color (e.g., red, green, blue, etc.) would have the same result as the lollipops 10 used in this treatment procedure.
- the patent typically consumed each medicated lollipop 10 in approximately 15-20 minutes (or between 15 and 20 minutes, inclusive). After consuming each of the medicated lollipops 10 , the patient did not orally ingest any other food or drink items for at least one-half (1 ⁇ 2) hour after the consumption of each medicated lollipop 10 .
- An upper endoscopy image of the patient's esophagus was taken before and after the treatment with the medicated lollipops 10 .
- the peripheral wall of the patient's esophagus contained white exudates with numerous eosinophiles, as well as ridges, furrows, or rings on the esophagus wall.
- a clear endoscopic image of the patient's esophagus was obtained following the abovedescribed treatment.
- the post-treatment upper/proximal endoscopic image revealed that the peripheral wall of the patient's esophagus was totally clear (i.e., it did not contain the white exudates comprising eosinophiles that were clearly present prior to the treatment).
- the post-treatment endoscopy performed on the patient revealed generally the same results for the distal esophagus (i.e., the portion of the esophagus closest to the stomach), namely that the distal esophagus also did not contain the white exudates comprising eosinophiles.
- biopsies that were performed on the patient in conjunction with the post-treatment upper endoscopy also confirmed the absence of eosinophiles.
- the medicated lollipops 10 resulted in an endoscopic image illustrating an esophagus free of white exudates, whereas an elemental diet and very limited food intake failed to do so for this same patient.
- the medicated lollipops 10 are an effective means by which to treat, reduce, and generally alleviate esophageal inflammation resulting from Eosinophilic Esophagitis (EoE) using a relatively low dosage of a corticosteroid (e.g., budesonide).
- a corticosteroid e.g., budesonide
- the treatment described herein, which used the medicated lollipops 10 resulted in a distal esophagus that was far more clean than that which is possible with the conventional methods that are used to treat Eosinophilic Esophagitis (EoE).
- EoE Eosinophilic Esophagitis
- these conventional methods of EoE treatment are unable to heal the distal portion of the esophagus due to their lack of coverage in the distal areas of the esophagus.
- FIG. 16 A post-treatment biopsy slide 30 of the patient's esophageal tissue is illustrated in FIG. 16 .
- the basal cell layer of the patient's esophagus exhibited a normal cell structure.
- the post-treatment biopsy slide 30 in this figure clearly demonstrates that the patient's Eosinophilic Esophagitis (EoE) was effectively treated by the consumption of the medicated lollipops 10 over the six week time period.
- EoE Eosinophilic Esophagitis
- the patient was permitted to add additional types of food to his diet, which were not permitted prior to the treatment.
- This permitted addition of other foods to the patient's diet significantly improved the patient's quality of life because he was now permitted to enjoy other types of food without worrying about aggravating the symptoms associated with his Eosinophilic Esophagitis (EoE).
- the aforedescribed medicated hard candy product 10 , 20 offers numerous advantages.
- the medicated hard candy product 10 , 20 and the treatment method using the same, effectively treats eosinophilic esophagitis without subjecting the patient to the unpleasant limitations of an elemental diet.
- the medicated hard candy product 10 , 20 sufficiently coats substantially the full length of the peripheral wall of the esophagus so as to effectively treat eosinophilic esophagitis throughout the entire esophagus.
- the medicated hard candy product 10 , 20 effectively treats eosinophilic esophagitis without a significant portion of the swallowed medicated product being wasted by failing to contact the esophagus wall.
- the medicated candy product generally flows down the esophagus wall without a significant portion being conveyed down the central portion of the esophagus, where it would just be wasted.
- the medicated hard candy product described herein advantageously maximizes the time during which the corticosteroid in the product is in contact with the mucosal layer of the esophagus wall (i.e., it maximizes the contact time of the corticosteroid with the mucosal layer of the esophagus wall).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
A medicated hard candy product for treating eosinophilic esophagitis (EoE) is disclosed herein. The medicated hard candy product includes a hard candy base material, the hard candy base material forming a substantially rigid candy product after being heated and permitted to cool for a predetermined time period; and a corticosteroid, the corticosteroid being intermixed with the hard candy base material. The medicated hard candy product is configured to reduce or alleviate esophageal inflammation and/or symptoms associated therewith in an individual when orally administered thereto. In one or more embodiments, the corticosteroid comprises one of: (i) budesonide, (ii) fluticasone, (iii) ciclesonide, (iv) beclomethasone dipropionate, and (v) mometasone furoate. Also, in one or more embodiments, the medicated hard candy product is in the form of a lollipop or lozenge. A method of treating, reducing, or alleviating esophageal inflammation in an individual, which utilizes the medicated hard candy product, is also disclosed herein.
Description
- This patent application is a continuation of U.S. patent application Ser. No. 16/159,564, entitled “Medicated Hard Candy Product For Treating Esophageal Inflammation And A Method Using The Same”, filed on Oct. 12, 2018; which is a continuation-in-part of U.S. patent application Ser. No. 14/720,918, entitled “Medicated Hard Candy Product For Treating Esophageal Inflammation And A Method Using The Same”, filed on May 25, 2015, and further claims the benefit of U.S. Provisional Patent Application No. 62/002,954, entitled “Medicated Hard Candy Product For Treating Esophageal Inflammation And A Method Using The Same”, filed on May 26, 2014, the disclosure of each of which is hereby incorporated by reference as if set forth in their entireties herein.
- Not Applicable.
- Not Applicable.
- Not Applicable.
- The invention generally relates to a medicated hard candy product. More particularly, the invention relates to a medicated hard candy product for treating esophageal inflammation and a method using the same.
- Eosinophilic esophagitis (EoE) is an allergic inflammatory condition of the esophagus that involves eosinophiles, a type of white blood cell. The typical symptoms of eosinophilic esophagitis (EoE) are difficulty swallowing, food impaction, and heartburn. Presently, there is no cure for eosinophilic esophagitis (EoE). One of the limited ways of treating eosinophilic esophagitis is with an elemental diet, or by removing allergenic foods. The dietary management approach is very challenging for the patient, and is often met with great resistance in adults and children alike. At this time, the overall treatment goal for eosinophilic esophagitis is to prevent the damaging inflammation that occurs due to migration of eosinophiles into the esophagus. If eosinophilic esophagitis is left untreated, the patient will gradually lose the ability to swallow, and eventually will be forced onto a feeding tube in order to survive.
- Therefore, what is needed is a medicated hard candy product for treating esophageal inflammation that effectively treats eosinophilic esophagitis without subjecting the patient to the unpleasant limitations of an elemental diet. Moreover, a medicated hard candy product is needed that sufficiently coats substantially the full length of the peripheral wall of the esophagus so as to effectively treat eosinophilic esophagitis throughout the entire esophagus. Furthermore, there is a need for a medicated hard candy product that effectively treats eosinophilic esophagitis without a significant portion of the swallowed medicated product being wasted by failing to contact the esophagus wall. In addition, there is a need for a treatment method using a medicated hard candy product that has the abovementioned attributes.
- Accordingly, the present invention is directed to a medicated hard candy product for treating esophageal inflammation and a method using the same that substantially obviates one or more problems resulting from the limitations and deficiencies of the related art.
- In accordance with one or more embodiments of the present invention, there is provided a medicated hard candy product that includes a hard candy base material, the hard candy base material forming a substantially rigid candy product after being heated and permitted to cool for a predetermined time period; and a corticosteroid, the corticosteroid being intermixed with the hard candy base material. The medicated hard candy product is configured to reduce or alleviate esophageal inflammation or symptoms associated therewith in an individual when orally administered thereto.
- In a further embodiment of the present invention, the hard candy base material comprises a sugar-free dry powder base prior to being heated.
- In yet a further embodiment, the corticosteroid comprises one of: (i) budesonide, (ii) fluticasone, (iii) ciclesonide, (iv) beclomethasone dipropionate, and (v) mometasone furoate.
- In still a further embodiment, the medicated hard candy product comprises between approximately 0.25 milligrams and approximately 1.0 milligrams of the corticosteroid.
- In yet a further embodiment, the medicated hard candy product contains no water after being heated and permitted to cool for the predetermined time period.
- In still a further embodiment, no water is used in the process of making the medicated hard candy product.
- In yet a further embodiment, the medicated hard candy product is in the form of a lollipop or sucker.
- In still a further embodiment, the medicated hard candy product is in the form of a lozenge.
- In accordance with one or more other embodiments of the present invention, there is provided a medicated hard candy product that includes a hard candy base material, the hard candy base material forming a substantially rigid candy product after being heated and permitted to cool for a predetermined time period; and a corticosteroid, the corticosteroid being intermixed with the hard candy base material, the corticosteroid comprising one of: (i) budesonide, (ii) fluticasone, (iii) ciclesonide, (iv) beclomethasone dipropionate, and (v) mometasone furoate. The medicated hard candy product is configured to reduce or alleviate esophageal inflammation or symptoms associated therewith in an individual when orally administered thereto; and the medicated hard candy product is in the form of a lollipop or a lozenge.
- In a further embodiment of the present invention, the hard candy base material comprises a sugar-free dry powder base prior to being heated.
- In yet a further embodiment, the medicated hard candy product contains no water after being heated and permitted to cool for the predetermined time period.
- In still a further embodiment, no water is used in the process of making the medicated hard candy product.
- In yet a further embodiment, the medicated hard candy product is in the form of a lollipop.
- In still a further embodiment, the medicated hard candy product is in the form of a lozenge.
- In accordance with yet one or more other embodiments of the present invention, there is provided a method of treating, reducing, or alleviating esophageal inflammation in an individual comprising orally administering to the individual a medicated hard candy product, the medicated hard candy product comprising a hard candy base material, the hard candy base material forming a substantially rigid candy product after being heated and permitted to cool for a predetermined time period; and a corticosteroid, the corticosteroid being intermixed with the hard candy base material, the corticosteroid comprising one of: (i) budesonide, (ii) fluticasone, (iii) ciclesonide, (iv) beclomethasone dipropionate, and (v) mometasone furoate.
- In a further embodiment of the present invention, the hard candy base material comprises a sugar-free dry powder base prior to being heated.
- In yet a further embodiment, the medicated hard candy product contains no water after being heated and permitted to cool for the predetermined time period.
- In still a further embodiment, no water is used in the process of making the medicated hard candy product.
- In yet a further embodiment, the medicated hard candy product is in the form of a lollipop or sucker.
- In still a further embodiment, the medicated hard candy product is in the form of a lozenge.
- It is to be understood that the foregoing general description and the following detailed description of the present invention are merely exemplary and explanatory in nature. As such, the foregoing general description and the following detailed description of the invention should not be construed to limit the scope of the appended claims in any sense.
- The invention will now be described, by way of example, with reference to the accompanying drawings, in which:
-
FIG. 1 is a perspective view of a medicated lollipop for treating esophageal inflammation, according to an embodiment of the invention, wherein the lollipop is illustrated with the wrapper thereon; -
FIG. 2 is another perspective view of the medicated lollipop ofFIG. 1 , wherein the lollipop is illustrated with the wrapper removed therefrom; -
FIG. 3 is a top view of the medicated lollipop ofFIG. 2 ; -
FIG. 4 is a front view of the medicated lollipop ofFIG. 2 ; -
FIG. 5 is a side view of the medicated lollipop ofFIG. 2 ; -
FIG. 6 is a transverse sectional view of the medicated lollipop ofFIG. 2 , wherein the section is cut along the cutting plane line A-A inFIG. 7 ; -
FIG. 7 is another front view of the medicated lollipop ofFIG. 2 , wherein the section cut lines are illustrated thereon; -
FIG. 8 is a longitudinal sectional view of the medicated lollipop ofFIG. 2 , wherein the section is cut along the cutting plane line B-B inFIG. 7 ; -
FIG. 9 is a perspective view of a medicated lozenge for treating esophageal inflammation, according to an embodiment of the invention, wherein the lozenge is illustrated with the wrapper thereon; -
FIG. 10 is another perspective view of the medicated lozenge ofFIG. 9 , wherein the lozenge is illustrated with the wrapper removed therefrom; -
FIG. 11 is a side view of the medicated lozenge ofFIG. 10 ; -
FIG. 12 is a top view of the medicated lozenge ofFIG. 10 , wherein the section cut lines are illustrated thereon; -
FIG. 13 is an end view of the medicated lozenge ofFIG. 10 ; -
FIG. 14 is a transverse sectional view of the medicated lozenge ofFIG. 10 , wherein the section is cut along the cutting plane line C-C inFIG. 12 ; -
FIG. 15 is a longitudinal sectional view of the medicated lozenge ofFIG. 10 , wherein the section is cut along the cutting plane line D-D inFIG. 12 ; and -
FIG. 16 illustrates a post-treatment biopsy slide for a patient that was treated using the medicated hard candy product of the present invention. - Throughout the figures, the same parts are always denoted using the same reference characters so that, as a general rule, they will only be described once.
- In one or more embodiments of the present invention, an orally-administered medicated hard candy product is provided that reduces or alleviates esophageal inflammation and/or symptoms associated therewith in an individual when orally administered thereto. In particular, the medicated hard candy reduces or alleviates esophageal inflammation that is caused by eosinophilic esophagitis (EoE). The medicated hard candy product generally comprises a hard candy base material, the hard candy base material forming a rigid or substantially rigid candy product after being heated and permitted to cool for a predetermined time period; and a corticosteroid, the corticosteroid being intermixed with the hard candy base material. The corticosteroid may comprise budesonide, fluticasone, ciclesonide, beclomethasone dipropionate, mometasone furoate, or another type of corticosteroid suitable for reducing or alleviating esophageal inflammation.
- The hard candy base material of the medicated hard candy product may comprise a sugar-free dry powder base that is suitable for preparing hand candy that can be orally administered and absorbed across the sublingual or buccal mucosa. In one or more embodiments, the hard candy base material may have a very low hygroscopicity, bitterness masking, and a low caloric value. The hard candy base material may also be non-cariogenic such that it does not promote tooth decay of the patient. For example, the hard candy base material may comprise Lollibase® as manufactured by Fagron Group BV.
- In order to make the medicated hard candy product more palatable to the patient, the medicated hard candy product may also include flavoring and sweeteners (e.g., sugar or a sugar substitute). For example, in one or more embodiments, the hard candy product may have a peppermint flavor or a fruit flavor (e.g., cherry flavor). Also, in order to make the medicated hard candy product more visually appealing to the patient, colors may be added to the hard candy mixture (e.g., the hard candy could be red, green, blue, or any other color that is desired).
- In a first illustrative embodiment, the medicated hard candy product is in the form of a medicated lollipop or
sucker 10. With reference toFIGS. 1-8 , it can be seen that the medicatedlollipop 10 generally compriseslollipop body portion 12 disposed on astick member 14. Thestick member 14 is embedded into thelollipop body portion 12 and serves as a handle for the user of the medicated lollipop 10 (seeFIG. 8 ). Also, as shown inFIG. 1 , thelollipop body portion 12 may comprise afoil wrapper 16 disposed therearound for hygienic purposes. When the user or patient is ready to consume the medicatedlollipop 10, he or she simply removes thefoil wrapper 16 from thelollipop body portion 12. - Now, referring to
FIGS. 2-7 , the structure of thelollipop body portion 12 will be described in more detail. As shown in these figures, it can be seen that thelollipop body portion 12 comprises a generally planarfront surface 12 a, a taperedcircular side surface 12 b, and a generally planarrear surface 12 c. As best shown inFIGS. 3 and 6 , thefront surface 12 a is disposed generally parallel to therear surface 12 c. Also, with reference toFIGS. 3 and 5 , it can be seen that thelollipop body portion 12 is provided with a rounded frontperipheral edge 18. InFIG. 3 , it can be seen that the rounded frontperipheral edge 18 is provided at the location where thefront surface 12 a adjoins the taperedcircular side surface 12 b. Advantageously, the rounded frontperipheral edge 18 of thelollipop body portion 12 substantially minimizes the risk that a user of the medicatedlollipop 10 will inadvertently cut his or her tongue on a sharp edge of thelollipop body portion 12. - In a second illustrative embodiment, the medicated hard candy product is in the form of a medicated
lozenge 20. With reference toFIGS. 9-15 , it can be seen that the medicatedlozenge 20 generally comprises anellipsoidal body portion 22 with flattened top and bottom surfaces. As shown inFIG. 9 , similar to thelollipop body portion 12, thelozenge body portion 22 may comprise afoil wrapper 24 disposed therearound for hygienic purposes. When the user or patient is ready to consume the medicatedlozenge 20, he or she simply removes thefoil wrapper 24 from thelozenge body portion 22. - Now, referring to
FIGS. 10-15 , the structure of thelozenge body portion 22 will be described in more detail. As shown in these figures, it can be seen that thelozenge body portion 22 comprises a generally planarfront surface 22 a, acurved side surface 22 b, and a generally planarrear surface 22 c. As best shown inFIGS. 11 and 13-15 , thefront surface 22 a is disposed generally parallel to therear surface 22 c. Also, with reference again toFIGS. 11 and 13-15 , it can be seen that thelozenge body portion 22 is provided with a roundedperipheral edges 26 circumscribing the front and rear edges thereof. As shown in these figures, it can be seen that the roundedperipheral edges 26 are provided at the location where thefront surface 22 a adjoins thecurved side surface 22 b and at the location where therear surface 22 c adjoins thecurved side surface 22 b. Advantageously, the roundedperipheral edges 26 of thelozenge body portion 22 substantially minimize the risk that a user of the medicatedlozenge 20 will inadvertently cut his or her tongue on a sharp edge of thelozenge body portion 22. - In one or more embodiments, the medicated hard candy product (e.g., the
lollipop 10 or the lozenge 20) may comprise between approximately 0.1 milligrams and approximately 2.0 milligrams of the corticosteroid (e.g., budesonide), or between 0.1 milligrams and 2.0 milligrams of the corticosteroid (e.g., budesonide). More preferably, in one or more embodiments, the medicated hard candy product (e.g., thelollipop 10 or the lozenge 20) may comprise between approximately 0.25 milligrams and approximately 1.0 milligrams of the corticosteroid (e.g., budesonide), or between 0.25 milligrams and 1.0 milligrams of the corticosteroid (e.g., budesonide). Still even more preferably, in one or more embodiments, the medicated hard candy product (e.g., thelollipop 10 or the lozenge 20) may comprise approximately 0.5 milligrams of the corticosteroid (e.g., budesonide), or 0.5 milligrams of the corticosteroid (e.g., budesonide). The amounts (in units of mass) of the corticosteroid in these embodiments have been determined such that the amount of the corticosteroid is sufficient to effectively reduce or alleviate esophageal inflammation and/or the symptoms associated therewith in an individual caused by eosinophilic esophagitis (EoE), yet not result in an excessive amount of the corticosteroid being delivered to the individual, which may produce negative side effects therefrom. In general, when ranges of a particular substance (e.g., a corticosteroid) are specified in this disclosure, the ranges are inclusive of the values encompassed within the specified range and the upper and lower limit boundaries themselves (e.g., between 0.1 and 2.0 milligrams includes the milligram values between the lower limit of 0.1 milligrams and the upper limit of 2.0 milligrams, as well as the lower and upper limit values of 0.1 and 2.0 milligrams). - In one or more embodiments, when the medicated hard candy product is provided in the form of the medicated
lollipop 10, the overall mass of thelollipop 10 may be between approximately 4.0 grams and approximately 17.0 grams (or between 4.0 grams and 17.0 grams). More preferably, in one or more embodiments, when the medicated hard candy product is provided in the form of the medicatedlollipop 10, the overall mass of thelollipop 10 may be between approximately 6.5 grams and approximately 12.0 grams (or between 6.5 grams and 12.0 grams). Still even more preferably, in one or more embodiments, the overall mass of thelollipop 10 may be approximately 8.5 grams (or 8.5 grams). The overall masses of thelollipop 10 in these embodiments have been determined such that thelollipop 10 is capable of delivering a requisite amount of the corticosteroid, yet not be excessively large and difficult to consume. - In one exemplary embodiment, when the medicated hard candy product is provided in the form of the medicated
lollipop 10, the medicatedlollipop 10 has an overall mass with thestick member 14 of approximately 9.141 grams, and has an overall mass without thestick member 14 of approximately 8.437 grams. In this exemplary embodiment, the medicatedlollipop 10 is provided with 1.0 milligram or 0.001 grams of budesonide, so that the medicatedlollipop 10 contains approximately 0.0119 percent budesonide by weight (i.e., without considering the weight of the stick member 14). Also, in one or more other embodiments, the medicatedlollipop 10 may contain at least 0.003 percent of the corticosteroid (e.g., budesonide) by weight (i.e., 0.25 milligrams of the corticosteroid in a medicatedlollipop 10 weighing 8.5 grams without the stick member 14) so that the amount of the corticosteroid is sufficient to effectively reduce or alleviate esophageal inflammation and/or the symptoms associated esophageal inflammation in an individual caused by eosinophilic esophagitis (EoE). - In one or more further embodiments, the top end of the
lollipop stick member 14 is coated with an anti-fungal medication. Advantageously, the anti-fungal medication on the top end of thelollipop stick member 14 treats oropharyngeal candidiasis (i.e., oral and esophageal thrush), which may be caused by the corticosteroid delivered by the medicatedlollipop 10. As such, in this further embodiment, the patient initially consumes thelollipop body portion 12 that delivers the corticosteroid for treating eosinophilic esophagitis (EoE), and then the patient subsequently receives a predetermined dosage of the anti-fungal medication on the top end of thelollipop stick member 14, which has been exposed after thelollipop body portion 12 has been consumed, for treating the oropharyngeal candidiasis. This inventive two-step treatment method not only effectively treats eosinophilic esophagitis (EoE), but also effectively treats any oropharyngeal candidiasis resulting from the consumption of the corticosteroid in thelollipop 10. The anti-fungal medication applied to the top end of thelollipop stick member 14 may comprise nystatin, Diflucan, fluconazole, Mycelex Troche, clotrimazole, Mycostatin, Nilstat, Bio-Statin, miconazole, ketoconazole, Amphocin, Sporanox PulsePak, Fungizone, gentian violet, itraconazole, amphotericin b, miconazole, Oravig, Sporanox, Noxafil, Onmel, and posaconazole, or another type of anti-fungal medication suitable for reducing or alleviating oral and/or esophageal thrush. In addition, similar to that described above for the hard candy product, the top end of thelollipop stick member 14 may have a peppermint flavor or a fruit flavor (e.g., a cherry flavor) to make the unpleasant flavor (e.g., bitter flavor) of the anti-fungal medication more tolerable for the patient. - In one exemplary embodiment, the anti-fungal medication applied to the top end of the
lollipop stick member 14 is nystatin. Nystatin is not absorbed into the bloodstream of the patient. In this exemplary embodiment, the dosage of nystatin provided on thelollipop stick member 14 is functionally equivalent to 400,000 to 600,000 international units (IU) in an oral suspension form. In this exemplary embodiment, this dosage is administered to the patient four times per day. - Now, a first exemplary procedure for making the medicated
lollipop 10 will be described in detail. First of all, the necessary quantities (e.g., percentage amounts) of each of the requisite ingredients for the medicatedlollipop 10 are determined (i.e., calculated) and procured. Of course, these prescribed quantities of ingredients are dependent upon the lollipop batch size that is to be made. In particular, a predetermined quantity of the following ingredients will be prepared for the batch of medicated lollipops 10: (i) a predetermined quantity of a corticosteroid (e.g., budesonide), (ii) a predetermined quantity of water, and (iii) a predetermined quantity of the hard candy base material (e.g., Lollibase®). Also, optionally, if the user or patient wants the medicatedlollipops 10 to be flavored, a flavoring substance (e.g., peppermint or a fruit flavor) may also be added as an ingredient in the mixture. Similarly, if the medicatedlollipops 10 are to be formed having a specific color, a coloring substance may also be added as another optional ingredient in the mixture. - Once the necessary ingredients are procured, the next step in the exemplary procedure is to add the hard candy base material and the water into a suitable beaker. Then, the solution of the hard candy base material and the water are heated or “cooked” using a suitable heating device (e.g., a hotplate). Next, when the solution reaches a temperature of approximately 148 degrees Celsius (298.4 degrees Fahrenheit), the beaker with the solution of the hard candy base material and water are removed from the heating device (e.g., a hotplate). Then, the corticosteroid (e.g., budesonide) and the optional flavoring are quickly added to the solution, and the solution is stirred so as to adequately mix the constituent ingredients. After stirring the ingredients together, the solution is poured into lollipop or sucker molds that form the shape of the medicated
lollipops 10. Prior to pouring the solution into the molds, the lollipop molds are basted with a non-sticking substance (e.g., canola oil) and the lollipop sticks 14 are properly positioned in the molds. If the solution begins to solidify or harden before it is completely poured into all of the lollipop molds, it may be necessary to reheat the solution, and then finish the pouring thereof into the molds. Finally, after being poured into the molds, the lollipops are allowed to cool and solidify for a predetermined time period (e.g., for a duration of at least two (2) hours) before they are wrapped with thewrappers 16. It is to be understood that a similar procedure to that described above may be used for forming the medicatedlozenges 20, except that nosticks 14 will be necessary and the molds utilized will form the shape of thelozenge body portion 22, rather than the shape of thelollipop body portion 12. - Even though water is used in the first exemplary procedure for making the medicated
lollipop 10, the final medicated hard candy product (e.g., the medicated lollipop 10) contains no residual water therein because all of the water is boiled off when the solution is heated to a temperature of approximately 148 degrees Celsius (298.4 degrees Fahrenheit). - Next, a second exemplary procedure for making the medicated
lollipop 10 will be described in detail. The second exemplary procedure for making the medicatedlollipop 10 is similar in most respects to the first exemplary procedure described above, except that no water is used in the process of making the medicatedlollipop 10. Initially, the necessary quantities (e.g., percentage amounts) of each of the requisite ingredients for the medicatedlollipop 10 are determined (i.e., calculated) and procured. Of course, these prescribed quantities of ingredients are dependent upon the lollipop batch size that is to be made. In particular, a predetermined quantity of the following ingredients will be prepared for the batch of medicated lollipops 10: (i) a predetermined quantity of a corticosteroid (e.g., budesonide) and (ii) a predetermined quantity of the hard candy base material (e.g., Lollibase®). Also, optionally, if the user or patient wants the medicatedlollipops 10 to be flavored, a flavoring substance (e.g., peppermint or a fruit flavor) may also be added as an ingredient in the mixture. Similarly, if the medicatedlollipops 10 are to be formed having a specific color, a coloring substance may also be added as another optional ingredient in the mixture. - Once the necessary ingredients are procured, the next step in the second exemplary procedure is to fill a suitable beaker with the hard candy base material. Then, the hard candy base material in the beaker is heated or “cooked” using a suitable heating device (e.g., a hotplate). Next, when the hard candy base material liquefies and reaches a temperature of approximately 148 degrees Celsius (298.4 degrees Fahrenheit), the beaker with the liquefied hard candy base material is removed from the heating device (e.g., a hotplate). Then, the corticosteroid (e.g., budesonide) and the optional flavoring are quickly added to the liquefied hard candy base material, and the solution is stirred so as to adequately mix the constituent ingredients. After stirring the ingredients together, the solution is poured into lollipop or sucker molds that form the shape of the medicated
lollipops 10. Prior to pouring the solution into the molds, the lollipop molds are basted with a non-sticking substance (e.g., canola oil) and the lollipop sticks 14 are properly positioned in the molds. If the solution begins to solidify or harden before it is completely poured into all of the lollipop molds, it may be necessary to reheat the solution, and then finish the pouring thereof into the molds. Finally, after being poured into the molds, the lollipops are allowed to cool and solidify for a predetermined time period (e.g., for a duration of at least two (2) hours) before they are wrapped with thewrappers 16. It is to be understood that a similar procedure to that described above may be used for forming the medicatedlozenges 20, except that nosticks 14 will be necessary and the molds utilized will form the shape of thelozenge body portion 22, rather than the shape of thelollipop body portion 12. - In the further embodiment described above, when the top end of the
lollipop stick member 14 is coated with an anti-fungal medication, the top ends of the lollipop sticks 14 are initially coated with the anti-fungal medication (i.e., in stage one), and then the lollipop sticks 14 are subsequently positioned in the molds so that the solution containing the corticosteroid and the hard candy base material is able to solidify on the lollipop sticks 14 (i.e., in stage two). - Advantageously, when no water is used in the process of making the medicated
lollipop 10, the shelf life of the medicatedlollipop 10 is increased from 30 days (i.e., when water is used in the process) to a shelf life of 6 months (i.e., when no water is used in the process). - In one or more embodiments, the hard candy base material (i.e., lollipop base material) used in the abovedescribed procedure is gluten-free, citric acid free, and sugar free. In these one or more embodiments, the hard candy base material generally comprises a blend or mixture of sugar alcohols (i.e., polyalcohols) from natural sources. Because the hard candy base material is a polyalcohol, it turns into a liquid when boiled. Also, in these one or more embodiments, the hard candy base material does not promote tooth decay. As described above in the exemplary procedure, the other main ingredients utilized in the process of making the lollipops, other than water, are a corticosteroid in the form of budesonide, pure canola oil to prevent the lollipops from sticking to the mold(s), and the optional natural flavor or flavors (e.g., peppermint). As alternative to, or in addition to peppermint flavoring, the following other natural flavors may be utilized in the solution used for making the medicated lollipops 10: almond, banana, blueberry, cherry, chocolate, cranberry, cinnamon, caramel, maple, pomegranate, raspberry, strawberry, toffee, licorice, lemon, orange, grapefruit, key lime, lime, pear, spearmint, tangerine, and wintergreen.
- Now, the results of an effective treatment procedure for alleviating the symptoms of Eosinophilic Esophagitis (EoE) that was performed using the abovedescribed medicated
lollipops 10 will be explained in detail. The treatment procedure was performed on the EoE patient for a time duration of approximately six (6) weeks. During each day of treatment, the patient orally ingested two (2) medicatedlollipops 10. Each of the medicatedlollipops 10 contained approximately 0.5 milligrams (MG) of budesonide. As such, the dosage of medication (budesonide) that the patient received during the treatment procedure was generally 0.5 MG BID (i.e., twice per day). The shelf life of the medicatedlollipops 10 that were used during the treatment was approximately six (6) months. Also, the medicatedlollipops 10 that were used during the treatment were peppermint-flavored, but because the flavoring is in no way connected to the medication itself, it is readily apparent that other flavors, or medicatedlollipops 10 with no flavoring would have the same result as thelollipops 10 used in this treatment procedure. In addition, the medicatedlollipops 10 that were used during the treatment were clear (i.e., they had no coloring added thereto), but because the coloring, like the flavoring, is in no way connected to the medication itself, it is readily apparent that medicatedlollipops 10 having a particular color (e.g., red, green, blue, etc.) would have the same result as thelollipops 10 used in this treatment procedure. - During the treatment, the patent typically consumed each medicated
lollipop 10 in approximately 15-20 minutes (or between 15 and 20 minutes, inclusive). After consuming each of the medicatedlollipops 10, the patient did not orally ingest any other food or drink items for at least one-half (½) hour after the consumption of each medicatedlollipop 10. - An upper endoscopy image of the patient's esophagus was taken before and after the treatment with the medicated
lollipops 10. Before treatment, the peripheral wall of the patient's esophagus contained white exudates with numerous eosinophiles, as well as ridges, furrows, or rings on the esophagus wall. In stark contrast, a clear endoscopic image of the patient's esophagus was obtained following the abovedescribed treatment. The post-treatment upper/proximal endoscopic image revealed that the peripheral wall of the patient's esophagus was totally clear (i.e., it did not contain the white exudates comprising eosinophiles that were clearly present prior to the treatment). The post-treatment endoscopy performed on the patient revealed generally the same results for the distal esophagus (i.e., the portion of the esophagus closest to the stomach), namely that the distal esophagus also did not contain the white exudates comprising eosinophiles. In addition, biopsies that were performed on the patient in conjunction with the post-treatment upper endoscopy also confirmed the absence of eosinophiles. As such, the medicatedlollipops 10 resulted in an endoscopic image illustrating an esophagus free of white exudates, whereas an elemental diet and very limited food intake failed to do so for this same patient. Consequently, it is readily apparent that the medicatedlollipops 10 are an effective means by which to treat, reduce, and generally alleviate esophageal inflammation resulting from Eosinophilic Esophagitis (EoE) using a relatively low dosage of a corticosteroid (e.g., budesonide). Also, the treatment described herein, which used the medicatedlollipops 10, resulted in a distal esophagus that was far more clean than that which is possible with the conventional methods that are used to treat Eosinophilic Esophagitis (EoE). Unlike the treatment procedure described herein, these conventional methods of EoE treatment are unable to heal the distal portion of the esophagus due to their lack of coverage in the distal areas of the esophagus. - A
post-treatment biopsy slide 30 of the patient's esophageal tissue is illustrated inFIG. 16 . As shown inFIG. 16 , after the patient ingested the medicatedlollipops 10 over the six week time period, the basal cell layer of the patient's esophagus exhibited a normal cell structure. In thenormal biopsy slide 30 ofFIG. 16 , there are no eosinophiles present. As such, thepost-treatment biopsy slide 30 in this figure clearly demonstrates that the patient's Eosinophilic Esophagitis (EoE) was effectively treated by the consumption of the medicatedlollipops 10 over the six week time period. - Advantageously, after the patient's doctor examined the clean endoscopic images, the patient was permitted to add additional types of food to his diet, which were not permitted prior to the treatment. This permitted addition of other foods to the patient's diet significantly improved the patient's quality of life because he was now permitted to enjoy other types of food without worrying about aggravating the symptoms associated with his Eosinophilic Esophagitis (EoE).
- It is readily apparent that the aforedescribed medicated
hard candy product hard candy product hard candy product hard candy product - Any of the features, attributes, or steps of the above described embodiments and variations can be used in combination with any of the other features, attributes, and steps of the above described embodiments and variations as desired.
- Although the invention has been shown and described with respect to a certain embodiment or embodiments, it is apparent that this invention can be embodied in many different forms and that many other modifications and variations are possible without departing from the spirit and scope of this invention.
- Moreover, while exemplary embodiments have been described herein, one of ordinary skill in the art will readily appreciate that the exemplary embodiments set forth above are merely illustrative in nature and should not be construed as to limit the claims in any manner. Rather, the scope of the invention is defined only by the appended claims and their equivalents, and not, by the preceding description.
Claims (11)
1. A method of treating, reducing, or alleviating esophageal inflammation in an individual comprising orally administering to said individual a medicated hard candy product, said medicated hard candy product comprising:
a hard candy base material, said hard candy base material forming a substantially rigid candy product after being heated and permitted to cool for a predetermined time period; and
a corticosteroid, said corticosteroid being intermixed with said hard candy base material, said corticosteroid comprising one of: (i) budesonide, (ii) fluticasone, (iii) ciclesonide, (iv) beclomethasone dipropionate, and (v) mometasone furoate.
2. The method according to claim 1 , wherein said hard candy base material comprises a sugar-free dry powder base prior to being heated.
3. The method according to claim 1 , wherein said medicated hard candy product contains no water after being heated and permitted to cool for said predetermined time period.
4. The method according to claim 1 , wherein no water is used in the process of making said medicated hard candy product, thereby substantially increasing a shelf life of said medicated hard candy product.
5. The method according to claim 4 , wherein said shelf life of said medicated hard candy product is approximately 6 months.
6. The method according to claim 1 , wherein said medicated hard candy product is in the form of a lollipop or sucker.
7. The method according to claim 1 , wherein said medicated hard candy product is in the form of a lozenge.
8. The method according to claim 1 , wherein said medicated hard candy product comprises between approximately 0.25 milligrams and approximately 2.0 milligrams of said corticosteroid.
9. The method according to claim 8 , wherein said medicated hard candy product comprises between approximately 0.25 milligrams and approximately 1.0 milligrams of said corticosteroid.
10. The method according to claim 1 , wherein the overall mass of said medicated hard candy product is between approximately 4.0 grams and approximately 17.0 grams.
11. The method according to claim 1 , wherein said corticosteroid of said medicated hard candy product is effective to treat esophageal inflammation and/or the symptoms associated therewith caused by eosinophilic esophagitis.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/493,698 US20220023202A1 (en) | 2014-05-26 | 2021-10-04 | Medicated Hard Candy Product For Treating Esophageal Inflammation And A Method Using The Same |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462002954P | 2014-05-26 | 2014-05-26 | |
US14/720,918 US20150335572A1 (en) | 2014-05-26 | 2015-05-25 | Medicated Hard Candy Product For Treating Esophageal Inflammation And A Method Using The Same |
US16/159,564 US11135158B2 (en) | 2014-05-26 | 2018-10-12 | Medicated hard candy product for treating esophageal inflammation and a method using the same |
US17/493,698 US20220023202A1 (en) | 2014-05-26 | 2021-10-04 | Medicated Hard Candy Product For Treating Esophageal Inflammation And A Method Using The Same |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/159,564 Continuation US11135158B2 (en) | 2014-05-26 | 2018-10-12 | Medicated hard candy product for treating esophageal inflammation and a method using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220023202A1 true US20220023202A1 (en) | 2022-01-27 |
Family
ID=65434655
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/159,564 Active US11135158B2 (en) | 2014-05-26 | 2018-10-12 | Medicated hard candy product for treating esophageal inflammation and a method using the same |
US17/493,698 Pending US20220023202A1 (en) | 2014-05-26 | 2021-10-04 | Medicated Hard Candy Product For Treating Esophageal Inflammation And A Method Using The Same |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/159,564 Active US11135158B2 (en) | 2014-05-26 | 2018-10-12 | Medicated hard candy product for treating esophageal inflammation and a method using the same |
Country Status (1)
Country | Link |
---|---|
US (2) | US11135158B2 (en) |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USD323417S (en) | 1990-08-08 | 1992-01-28 | Angela Cacia | Medicated lollipop |
USH1228H (en) | 1990-10-04 | 1993-09-07 | Medicated lollipop | |
US5674912A (en) | 1991-03-01 | 1997-10-07 | Warner-Lambert Company | Sunscreen-wound healing compositions and methods for preparing and using same |
US5658956A (en) | 1991-03-01 | 1997-08-19 | Warner-Lambert Company | Bioadhesive-wound healing compositions and methods for preparing and using same |
US5762963A (en) | 1995-06-07 | 1998-06-09 | Emory University | Method and compositions for controlling oral and pharyngeal pain using capsaicinoids |
US5827527A (en) | 1997-03-24 | 1998-10-27 | Leonard; Dana B. | Medicated candy product |
US20020009478A1 (en) | 1998-08-24 | 2002-01-24 | Douglas Joseph Dobrozsi | Oral liquid mucoadhesive compositions |
EP1503737B1 (en) * | 2002-05-06 | 2009-01-07 | Elan Pharma International Limited | Nanoparticulate nystatin formulations |
US20040253307A1 (en) | 2003-02-04 | 2004-12-16 | Brian Hague | Sugar-free oral transmucosal solid dosage forms and uses thereof |
CA2591706A1 (en) | 2004-12-22 | 2006-06-29 | Schering Corporation | Pharmaceutical formulations |
US20070149466A1 (en) | 2005-07-07 | 2007-06-28 | Michael Milburn | Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders |
US8679545B2 (en) | 2005-11-12 | 2014-03-25 | The Regents Of The University Of California | Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract |
US8497258B2 (en) | 2005-11-12 | 2013-07-30 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
US8324192B2 (en) | 2005-11-12 | 2012-12-04 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
US8545537B2 (en) | 2007-06-21 | 2013-10-01 | Erin Murphy Matro | Developmental pacifier |
EP2488257B1 (en) | 2009-10-14 | 2018-05-02 | Symrise AG | Formulation with irritation reducing action comprising bisabolol and [6]-paradol |
US20140371179A1 (en) | 2013-06-13 | 2014-12-18 | Professional Compounding Centers Of America | Methods and Compositions for Treating Esophageal Diseases |
-
2018
- 2018-10-12 US US16/159,564 patent/US11135158B2/en active Active
-
2021
- 2021-10-04 US US17/493,698 patent/US20220023202A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20190060226A1 (en) | 2019-02-28 |
US11135158B2 (en) | 2021-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10441535B2 (en) | Nutraceutical confectionary composition containing caffeine and L-theanine | |
US20120035277A1 (en) | Liquid-filled chewable supplement | |
CN101820893A (en) | Granular jelly beverage for medication and process for producing the same | |
US20120164134A1 (en) | Sugar-free chewable supplement | |
US20060121092A1 (en) | Methods of producing coated products including active agent and products regarding same | |
US7935362B2 (en) | Over-coated product including consumable center and medicament | |
JP2018532702A (en) | Laxative formulation and manufacturing | |
US20220023202A1 (en) | Medicated Hard Candy Product For Treating Esophageal Inflammation And A Method Using The Same | |
US20060121093A1 (en) | Tableted products including active agent | |
AU645966B2 (en) | Method and compositions for noninvasive dose-to-effect administration of lipophilic drugs | |
US20150335572A1 (en) | Medicated Hard Candy Product For Treating Esophageal Inflammation And A Method Using The Same | |
WO2020051055A2 (en) | Cannabinoid and menthol gum and lozenge compositions and methods | |
US20120046354A1 (en) | Anti-oxidant lozenges for the prevention and treatment of radiation induced mucositis, precancerous lesions, oral cancer and other oral cavity mucosal disorders | |
US11857557B2 (en) | Oral dissolvable film containing vitamin D3 | |
EP1945181B1 (en) | Coated pharmaceutical composition for buccal release which comprises a consumable center and a medicament-containing coating | |
JP2002020278A (en) | Chewing gum for preventing cancer of oral cavity | |
EP1101491A2 (en) | Soft gelatine capsules containing olive oil | |
EP1951196A1 (en) | Tablets comprising a core and a medicament-containing coating for buccal release | |
RU2811131C1 (en) | Jelly candy | |
EP4366697A1 (en) | Gummy dosage forms | |
US11376227B2 (en) | Cannabinoid and menthol gum and lozenge compositions and methods | |
US8563030B1 (en) | Singultus-stopping article and composition | |
Abhishek et al. | A Review of Lozenges Containing Liquorice and Lemongrass for the Treatment of Sour Throat | |
US20230136537A1 (en) | Simethicone chewable composition | |
WO2008080809A2 (en) | Pharmaceutical composition containing psyllium and senna |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |